Literature DB >> 16146667

Two-generation reproduction and cross-foster studies of perfluorooctanesulfonate (PFOS) in rats.

Deanna J Luebker1, Marvin T Case, Raymond G York, John A Moore, Kristen J Hansen, John L Butenhoff.   

Abstract

Perfluorooctanesulfonate (PFOS) is a persistent acid found widely distributed in wildlife and humans. To understand the potential reproductive and developmental effects of PFOS, a two-generation reproduction study was conducted in rats. Male and female rats were dosed via oral gavage at dose levels of 0, 0.1, 0.4, 1.6, and 3.2 mg/(kg day) for 6 weeks prior to mating, during mating, and, for females, through gestation and lactation, across two generations. Due to substantial F1 neonatal toxicity observed in the 1.6 and 3.2 mg/(kg day) groups, continuation into the second generation was limited to F1 pups from the 0, 0.1, and 0.4 mg/(kg day) groups. No adverse effects were observed in F0 females or their fetuses upon caesarean sectioning at gestation day 10. Statistically significant reductions in body-weight gain and feed consumption were observed in F0 generation males and females at dose levels of 0.4 mg/(kg day) and higher, but not in F1 adults. PFOS did not affect reproductive performance (mating, estrous cycling, and fertility); however, reproductive outcome, as demonstrated by decreased length of gestation, number of implantation sites, and increased numbers of dams with stillborn pups or with all pups dying on lactation days 1-4, was affected at 3.2 mg/(kg day) in F0 dams. These effects were not observed in F1 dams at the highest dose tested, 0.4 mg/(kg day). Neonatal toxicity in F1 pups, as demonstrated by reduced survival and body-weight gain through the end of lactation, occurred at a maternal dose of 1.6 mg/(kg day) and higher while not at dose levels of 0.1 or 0.4 mg/(kg day) or in F2 pups at the 0.1 or 0.4 mg/(kg day) dose levels tested. In addition to these adverse effects, slight yet statistically significant developmental delays occurred at 0.4 (eye opening) and 1.6 mg/(kg day) (eye opening, air righting, surface righting, and pinna unfolding) in F1 pups. Based on these data, the NOAELs were as follows: reproductive function: F0> or =3.2 and F1> or =0.4 mg/(kg day); reproductive outcome: F0=1.6 and F1> or =0.4 mg/(kg day); overall parental effects: F0=0.1 and F1> or =0.4 mg/(kg day); offspring effects: F0=0.4 and F1> or =0.4 mg/(kg day). To distinguish between maternal and pup influences contributing to the perinatal mortality observed in the two-generation study, a follow-up cross-foster study was performed. Results of this study indicated that in utero exposure to PFOS causally contributed to post-natal pup mortality, and that pre-natal and post-natal exposure to PFOS was additive with respect to the toxic effects observed in pups.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16146667     DOI: 10.1016/j.tox.2005.07.018

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  41 in total

1.  Breastfeeding as a Predictor of Serum Concentrations of Per- and Polyfluorinated Alkyl Substances in Reproductive-Aged Women and Young Children: A Rapid Systematic Review.

Authors:  Brianna N VanNoy; Juleen Lam; Ami R Zota
Journal:  Curr Environ Health Rep       Date:  2018-06

2.  Proceedings of the Summit on Environmental Challenges to Reproductive Health and Fertility: executive summary.

Authors:  Tracey J Woodruff; Alison Carlson; Jackie M Schwartz; Linda C Giudice
Journal:  Fertil Steril       Date:  2008-02       Impact factor: 7.329

3.  Mixing of perfluorooctanesulfonic acid (PFOS) potassium salt with dipalmitoyl phosphatidylcholine (DPPC).

Authors:  H-J Lehmler; W Xie; G D Bothun; P M Bummer; B L Knutson
Journal:  Colloids Surf B Biointerfaces       Date:  2006-05-25       Impact factor: 5.268

4.  Longitudinal analysis reveals early-pregnancy associations between perfluoroalkyl sulfonates and thyroid hormone status in a Canadian prospective birth cohort.

Authors:  Anthony J F Reardon; Elham Khodayari Moez; Irina Dinu; Susan Goruk; Catherine J Field; David W Kinniburgh; Amy M MacDonald; Jonathan W Martin
Journal:  Environ Int       Date:  2019-05-28       Impact factor: 9.621

5.  Concentrations of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) and their associations with human semen quality measurements.

Authors:  James H Raymer; Larry C Michael; William B Studabaker; Geary W Olsen; Carol S Sloan; Timothy Wilcosky; David K Walmer
Journal:  Reprod Toxicol       Date:  2011-06-29       Impact factor: 3.143

6.  Comparison of polyfluoroalkyl compound concentrations in maternal serum and amniotic fluid: a pilot study.

Authors:  Cheryl R Stein; Mary S Wolff; Antonia M Calafat; Kayoko Kato; Stephanie M Engel
Journal:  Reprod Toxicol       Date:  2012-05-18       Impact factor: 3.143

7.  Peroxisome proliferator-activated receptors alpha, Beta, and gamma mRNA and protein expression in human fetal tissues.

Authors:  Barbara D Abbott; Carmen R Wood; Andrew M Watkins; Kaberi P Das; Christopher S Lau
Journal:  PPAR Res       Date:  2010-07-26       Impact factor: 4.964

8.  Development of PBPK models for PFOA and PFOS for human pregnancy and lactation life stages.

Authors:  Anne E Loccisano; Matthew P Longnecker; Jerry L Campbell; Melvin E Andersen; Harvey J Clewell
Journal:  J Toxicol Environ Health A       Date:  2013

9.  Correlations between prenatal exposure to perfluorinated chemicals and reduced fetal growth.

Authors:  Noriaki Washino; Yasuaki Saijo; Seiko Sasaki; Shizue Kato; Susumu Ban; Kanae Konishi; Rie Ito; Ayako Nakata; Yusuke Iwasaki; Koichi Saito; Hiroyuki Nakazawa; Reiko Kishi
Journal:  Environ Health Perspect       Date:  2008-11-04       Impact factor: 9.031

10.  Association between serum perfluorooctanoic acid (PFOA) and thyroid disease in the U.S. National Health and Nutrition Examination Survey.

Authors:  David Melzer; Neil Rice; Michael H Depledge; William E Henley; Tamara S Galloway
Journal:  Environ Health Perspect       Date:  2010-01-07       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.